



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 18, 2024

Michael Mason  
EVP, Chief Financial Officer and Treasurer  
Karyopharm Therapeutics Inc.  
85 Wells Ave., 2nd Floor  
Newton, MA 02459

**Re: Karyopharm Therapeutics Inc.**  
**Form 10-K for the year ended December 31, 2023**  
**Filed February 29, 2024**  
**File No. 001-36167**

Dear Michael Mason:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences